Benign Prostatic Hyperplasia (BPH) Clinical Trial
Official title:
Is Absorption of Irrigation Fluid a Problem in Thulium Laser Vaporization of the Prostate? A Prospective Investigation Using the Expired Breath Ethanol Test.
Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older
than 60 years.In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar
transurethral resection of the prostate (TUR-P) is the standard treatment. Especially in
frail patients, conventional TUR-P is associated with relevant and potentially deleterious
complications, e.g. TUR syndrome. Using isotonic saline, like in bipolar TUR-P and
transurethral laser vaporization (TUV-P), TUR syndrome can be prevented.
The short-term complication rate with the Thulium laser is similar to the rate described
after vaporisation with other laser systems18-23 and less than that with TUR-P.
Despite recent publications on the safety and complications with Thulium vaporisation of the
prostate, to the investigators knowledge, until now, no prospective trial has directly
assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser
vaporisation of the prostate.
The investigators therefore aim to investigate if absorption of irrigation fluid occurs
during Thulium Laser vaporisation of the prostate by expired breath ethanol test.
Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older
than 60 years.3 The clinical picture of the disease includes lower urinary tract symptoms
such as interrupted and weak urinary stream, nocturia, urgency and leaking and even sexual
dysfunction in some individuals. Medical therapy is usually the first-line treatment.
However, the efficacy of drugs like alpha-blockers is limited, and as disease progresses
more invasive treatment options have to be taken into consideration.
In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar transurethral
resection of the prostate (TUR-P) is the standard treatment. Especially in frail patients,
conventional TUR-P is associated with relevant and potentially deleterious complications.
The proportion of elderly patients on anticoagulation or antiplatelet therapy with cardial
comorbidities increases. Especially major bleeding and transurethral resection syndrome (TUR
syndrome) put these high-risk patients at a relevant perioperative risk.
TUR syndrome is caused by absorption of electrolyte-free irrigating fluid (which has to be
used in monopolar TUR-P), and consists of symptoms from the circulatory and nervous systems.
Mild forms are common and often go undiagnosed, while severe forms of the TUR syndrome are
potentially life-threatening.
Using isotonic saline, like in bipolar TUR-P and transurethral laser vaporization (TUV-P),
TUR syndrome can be prevented. Moreover, these techniques were thought to completely prevent
influx of irrigation fluid into the vascular system due to their excellent coagulation
properties.
However, the Zürich study group has demonstrated that in bipolar resection of the prostate
and with the Greenlight-Laser, significant intraoperative fluid absorption can occur. The
authors emphasized, that care must be taken if using this procedures in patients with
significant cardiovascular comorbidities, as large volume influx in patients with
significant cardiac comorbidities could result in dangerous complications.
Ethanol monitoring was first used in the late 1980's as an alternative to traditional
methods of measuring fluid absorption (i.e. measuring volumetric fluid balance and serum
sodium concentration). These techniques, however, are bothersome and must be carried out
meticulously to yield a valid figure of absorption. If a tracer amount of ethanol is added
to the irrigation fluid, the volume of fluid absorbed can be estimated from the amount of
ethanol measured in the patients' exhaled breath.
The expired-breath ethanol technique is an established method of investigating intra
operative absorption of irrigation fluid. Ethanol 1% is added to conventional isotonic 0.9%
saline for use as intra-operative irrigation. The absorption of irrigation fluid can be
estimated by measuring the end-expiratory ethanol concentrations with an alcometer.
During the last years, the Thulium laser has emerged as an alternative to other types of
lasers, combining the best features for performing vaporisation techniques: Thulium laser
has a wavelength of 2013 nm, and its target chromophore is water. The energy of the Thulium
laser has a high tissue absorption rate, producing effective vaporisation with scant depth
in the remaining tissue. As the properties of water remain unaltered until it reaches
boiling point, the effect of the laser on the tissue remains constant throughout the
surgical procedure.
The short-term complication rate with the Thulium laser is similar to the rate described
after vaporisation with other laser systems and less than that with TUR-P. Thus, Thulium
vaporisation of prostate has established as a standard procedure in many urological
departments including ours.
Despite recent publications on the safety and complications with Thulium vaporisation of the
prostate, to the investigators knowledge, until now, no prospective trial has directly
assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser
vaporisation of the prostate.
The investigators therefore aim to investigate if absorption of irrigation fluid occurs
during Thulium Laser vaporisation of the prostate by expired breath ethanol test.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03052049 -
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
|
N/A | |
Recruiting |
NCT04757116 -
Post-Market Study to Assess iTind Safety in Comparison to UroLift
|
N/A | |
Completed |
NCT03460873 -
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
|
||
Completed |
NCT01218243 -
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
|
Phase 2 | |
Completed |
NCT01566292 -
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00407953 -
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Phase 4 | |
Completed |
NCT03191734 -
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
N/A | |
Recruiting |
NCT04838769 -
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
|
N/A | |
Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
Completed |
NCT04032067 -
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT02505919 -
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
|
N/A | |
Completed |
NCT02855892 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
|
Phase 2 | |
Completed |
NCT02145208 -
Study to Assess the Efficacy of Medi-Tate iTind Device
|
N/A | |
Completed |
NCT00970632 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
|
Phase 3 | |
Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00945490 -
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
|
Phase 3 | |
Completed |
NCT00759135 -
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
|
Phase 2 | |
Completed |
NCT00224107 -
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
|
Phase 3 | |
Recruiting |
NCT04648176 -
Application of MOSES Technology in BPH
|
N/A | |
Terminated |
NCT00651807 -
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
|
Phase 2 |